Breast cancer in North America and Europe is the most frequently diagnosed cancer among women and is the second most fatal cancer. This is a key reason for why a consortium of Canadian researchers are banding together to develop methods for screening.

Teaming up with Thermo Fisher Scientific, the Ontario Institute for Cancer Research (OICR) and Queen’s University embarked on an academic and industrial collaboration aimed to accelerate developments in breast cancer research. According to Dr. John Bartlett, Director of OICR’s Transformative Pathology Program, “this study will demonstrate a paradigm that could be applied across multiple common cancers.” The study will use Thermo Fisher’s Oncomine Comprehensive Assay, a targeted, next-generation sequencing (NGS) research tool.

Learn more about the consortium’s approach to tackling breast cancer diagnosis in the future at OICR’s website and also take a behind the scenes look at the study in the video below:



 Stay updated on sequencing breakthroughs by subscribing to our sequencing blog



 Explore our comprehensive portfolio of sequencing solutions


 Contact us

 Have a question on which platform is right for you?